Medivolve Inc.
Medivolve Inc. 4NC.F Peers
See (4NC.F) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 4NC.F | €0.00 | N/A | 0 | 0.07 | €0.05 | N/A |
| TN8.DE | €354.75 | -0.23% | 133.9B | 23.71 | €14.96 | +0.39% |
| DAP.DE | €167.16 | -0.49% | 119.6B | 36.74 | €4.55 | +0.57% |
| ILU.DE | €74.51 | +1.57% | 11.8B | -13.90 | -€5.36 | N/A |
| QIA.DE | €39.56 | +1.06% | 8.6B | 104.11 | €0.38 | +3.12% |
| SYAB.DE | €11.06 | -0.18% | 2.4B | 27.65 | €0.40 | N/A |
| NN6.DE | €1.39 | +1.09% | 17.9M | -5.54 | -€0.25 | N/A |
| ECX.DE | €0.70 | -11.17% | 612.6K | -0.04 | -€19.55 | N/A |
Stock Comparison
4NC.F vs TN8.DE Comparison
4NC.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4NC.F stands at 0. In comparison, TN8.DE has a market cap of 133.9B. Regarding current trading prices, 4NC.F is priced at €0.00, while TN8.DE trades at €354.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4NC.F currently has a P/E ratio of 0.07, whereas TN8.DE's P/E ratio is 23.71. In terms of profitability, 4NC.F's ROE is N/A, compared to TN8.DE's ROE of +0.13%. Regarding short-term risk, 4NC.F is more volatile compared to TN8.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 4NC.F.